Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.48 |
| ▸ | KDR | P35968 | 11/20 | 0.48 |
| ▸ | FLT1 | P17948 | 3/20 | 0.45 |
| ▸ | FLT4 | P35916 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 6/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4219191 | 0.89 | KDR (0.48) | MAPK14KDRFLT1FLT4EGFR | |
| SCHEMBL4216555 | 0.87 | KDR (0.42) | MAPK14KDRFLT1FLT4EGFR | |
| SCHEMBL4048475 | 0.81 | EGFR (0.56) | MAPK14KDRFLT1FLT4EGFR | |
| SCHEMBL14451986 | 0.76 | KDR (0.39) | MAPK14KDRFLT1FLT4 | |
| SCHEMBL4049767 | 0.75 | KDR (0.62) | MAPK14KDR | |
| SCHEMBL5740699 | 0.74 | EGFR (0.46) | MAPK14KDRFLT1FLT4EGFR | |
| SCHEMBL4052170 | 0.74 | EGFR (0.41) | MAPK14KDRFLT1FLT4EGFR | |
| SCHEMBL17678081 | 0.71 | EPHX2 (0.59) | DRD3 | |
| SCHEMBL4108838 | 0.71 | MAPK14 (0.86) | MAPK14 | |
| SCHEMBL5740297 | 0.70 | KDR (0.46) | MAPK14KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183033-B1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | claimed |
| US-6982265-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-01-03 | — | — | US | claimed |
| EP-1669071-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7244733-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244733-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244733-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7112675-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060128709-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1669071-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1183033-B1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-6982265-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-01-03 | — | — | US | disclosed |
| EP-1183033-A4 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1183033-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071129-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128709-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | MAPK14 548/4885KDR 8/4885FLT1 4/4885 |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | MAPK14 548/4885KDR 8/4885FLT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.